Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 277Precursor Cell Lymphoblastic Leukemia-Lymphoma 55Recurrence 43Neoplasms, Plasma Cell 32Leukemia 29Lymphoma 25Neoplasms 23Vomiting 21Burkitt Lymphoma 20Lymphoma, Non-Hodgkin 19Nausea 17Immunoglobulin Light-chain Amyloidosis 17Lymphoma, Mantle-Cell 16Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 14Waldenstrom Macroglobulinemia 13Lymphoma, Follicular 13Breast Neoplasms 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Leukemia, Myeloid, Acute 10Lymphoma, B-Cell, Marginal Zone 9Amyloidosis 9Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 8Neoplasm Metastasis 7Hematologic Neoplasms 7Smoldering Multiple Myeloma 6Ovarian Neoplasms 6Lung Neoplasms 6

Interventions

perflutren 1Thalidomide 1Rocuronium 1Hypothermia, Induced 1Dexamethasone 1Bortezomib 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Renal Insufficiency, Chronic × Dexamethasone × Clear all
NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡